Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 8c
November 7, 2017 4:16 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.03), $0.08 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $43.92 million.
Sees Q4 combined net product sales from both HETLIOZ and Fanapt $42 to $48 million
For earnings history... More
